Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease.

Background: Approximately 15-20% of ulcerative colitis patients and 20-40% of those with Crohn's disease experience extraintestinal manifestations (EIMs) of their inflammatory bowel disease (IBD). Clinicians who treat IBD must manage EIMs affecting multiple organs that variably correlate with intest...

Full description

Bibliographic Details

Published in:	Digestive Diseases & Sciences Vol. 63; no. 4; pp. 825 - 834
Main Authors:	Fleisher, Mark, Marsal, Jan, Lee, Scott D., Frado, Laura E., Parian, Alyssa, Korelitz, Burton I., Feagan, Brian G.
Format:	review Journal Article
Published:	Springer Nature Apr2018
Online Access:	View this record in EBSCOhost